Lestaurtinib, a tyrosine kinase inhibitor, enhanced the in-vitro drug effects of the PARP1 inhibitor AG14361 in breast cancer treatment, partly by suppressing NF-κB signaling [68]. The gene discussed is PARP1; the disease is breast carcinoma.